{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T06:28:53Z","timestamp":1793082533436,"version":"4.5.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Family Kamprad Foundation","award":["20190024"],"award-info":[{"award-number":["20190024"]}]},{"name":"Swedish Heart and Lung Foundation","award":["20200150"],"award-info":[{"award-number":["20200150"]}]},{"name":"Swedish Government and Country Council ALF","award":["ALFGBG-824371"],"award-info":[{"award-number":["ALFGBG-824371"]}]},{"name":"Family Kamprad Foundation","award":["20190024"],"award-info":[{"award-number":["20190024"]}]},{"name":"Swedish Heart and Lung Foundation","award":["20200150"],"award-info":[{"award-number":["20200150"]}]},{"name":"Swedish Government and Country Council ALF","award":["ALFGBG-824371"],"award-info":[{"award-number":["ALFGBG-824371"]}]}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Risk stratification of patients according to chronic obstructive pulmonary disease severity is clinically important and forms the basis of therapeutic recommendations. No studies have examined the association for Global Initiative for Chronic Obstructive Lung Disease (GOLD) group A and group B patients with (A1 and B1, respectively) and without (A0 and B0, respectively) an exacerbation in the past year with future exacerbations, hospitalizations, and mortality in perspective with the new GOLD ABE classification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The aim was to examine the association between GOLD A0, A1, B0, B1, and E patients and future exacerbations, respiratory and cardiovascular hospitalizations, and mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this nationwide cohort study, we identified patients with a diagnosis of chronic obstructive pulmonary disease, aged \u226530\u2009years, and registered in the Swedish National Airway Register between January 2017 and August 2020. Patients were stratified in GOLD groups A0, A1, B0, B1, and E and were followed until January 2021 for exacerbations, hospitalizations, and mortality in national registries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>The 45,350 eligible patients included 25% A0, 4% A1, 44% B0, 10% B1, and 17% E. Moderate exacerbations, all-cause and respiratory hospitalizations, and all-cause and respiratory mortality increased by GOLD group A0-A1-B0-B1-E, except for moderate exacerbations, which were higher in A1 than in B0. Group B1 had a substantially higher hazard ratio for future exacerbation (2.56; 95% confidence interval [95% CI] 2.40\u20132.74), all-cause hospitalization (1.28; 1.21\u20131.35), and respiratory hospitalization (1.44; 1.27\u20131.62), but not all-cause (1.04; 0.91\u20131.18) or respiratory (1.13; 0.79\u20131.64) mortality than group B0. The exacerbation rate for group B1 was 0.6 events per patient-year versus 0.2 for group B0 (rate ratio, 2.55; 95% CI, 2.36\u20132.76). Results were similar for group A1 versus group A0.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Stratification of GOLD A and B patients with one or no exacerbation in the past year provides valuable information on future risk, which should influence treatment recommendations for preventive strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1164\/rccm.202209-1774oc","type":"journal-article","created":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T14:40:34Z","timestamp":1681224034000},"page":"163-175","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":45,"title":["Exacerbation Risk and Mortality in Global Initiative for Chronic Obstructive Lung Disease Group A and B Patients with and without Exacerbation History"],"prefix":"10.1093","volume":"208","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4387-4096","authenticated-orcid":false,"given":"Lowie E. G. W.","family":"Vanfleteren","sequence":"first","affiliation":[{"name":"COPD Center, Department of Respiratory Medicine and Allergology, Sahlgrenska University Hospital, Gothenburg, Sweden"},{"name":"Department of Internal Medicine and Clinical Nutrition and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3292-7471","authenticated-orcid":false,"given":"Anne","family":"Lindberg","sequence":"additional","affiliation":[{"name":"Division of Medicine\/The OLIN Unit, Department of Public Health and Clinical Medicine, Ume\u00e5 University, Ume\u00e5, Sweden; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caddie","family":"Zhou","sequence":"additional","affiliation":[{"name":"Center of Registers V\u00e4stra G\u00f6taland, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Nyberg","sequence":"additional","affiliation":[{"name":"School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6622-3838","authenticated-orcid":false,"given":"Caroline","family":"Stridsman","sequence":"additional","affiliation":[{"name":"Division of Medicine\/The OLIN Unit, Department of Public Health and Clinical Medicine, Ume\u00e5 University, Ume\u00e5, Sweden; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,7,15]]},"reference":[{"key":"2026012204413060100_bib1","year":"2023"},{"key":"2026012204413060100_bib2","doi-asserted-by":"crossref","first-page":"00253-2020","DOI":"10.1183\/23120541.00253-2020","article-title":"Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2015 and GOLD 2019 staging: a pooled analysis of individual patient data","volume":"6","author":"Garc\u00eda Castillo","year":"2020","journal-title":"ERJ Open Res"},{"key":"2026012204413060100_bib3","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S2213-2600(18)30002-X","article-title":"Prediction of mortality in patients with chronic obstructive pulmonary disease with the new Global Initiative for Chronic Obstructive Lung Disease 2017 classification: a cohort study","volume":"6","author":"Gedebjerg","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2026012204413060100_bib4","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.2147\/COPD.S194019","article-title":"Prevalence and prognostic ability of the GOLD 2017 classification compared to the GOLD 2011 classification in a Norwegian COPD cohort","volume":"14","author":"Le","year":"2019","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026012204413060100_bib5","doi-asserted-by":"crossref","first-page":"909","DOI":"10.2147\/COPD.S300299","article-title":"Adherence to treatment recommendations for chronic obstructive pulmonary disease\u2014results from the Swedish National Airway Register","volume":"16","author":"Larsson","year":"2021","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026012204413060100_bib6","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1164\/rccm.201710-2029OC","article-title":"Natural history of chronic obstructive pulmonary disease exacerbations in a general practice\u2013based population with chronic obstructive pulmonary disease","volume":"198","author":"Rothnie","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204413060100_bib7","doi-asserted-by":"crossref","first-page":"569","DOI":"10.2147\/COPD.S344669","article-title":"Disease trajectories and impact of one moderate exacerbation in Gold B COPD patients","volume":"17","author":"L\u00f8kke","year":"2022","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026012204413060100_bib8","first-page":"2318","article-title":"Risk for exacerbation, hospitalization and mortality in Global Initiative for Chronic Obstructive Lung Disease group B patients with and without exacerbations: a cohort study [abstract]","volume":"60","author":"Vanfleteren","year":"2022","journal-title":"Eur Respir J"},{"key":"2026012204413060100_bib9","doi-asserted-by":"crossref","first-page":"1833412","DOI":"10.1080\/20018525.2020.1833412","article-title":"The Swedish National Airway Register (SNAR): development, design and utility to date","volume":"7","author":"Stridsman","year":"2020","journal-title":"Eur Clin Respir J"},{"key":"2026012204413060100_bib10","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s10654-009-9350-y","article-title":"The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research","volume":"24","author":"Ludvigsson","year":"2009","journal-title":"Eur J Epidemiol"},{"key":"2026012204413060100_bib11","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1186\/1471-2458-11-450","article-title":"External review and validation of the Swedish National Inpatient Register","volume":"11","author":"Ludvigsson","year":"2011","journal-title":"BMC Public Health"},{"key":"2026012204413060100_bib12","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/pds.1294","article-title":"The new Swedish Prescribed Drug Register\u2014opportunities for pharmacoepidemiological research and experience from the first six months","volume":"16","author":"Wettermark","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026012204413060100_bib13","year":"2019"},{"key":"2026012204413060100_bib14","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s10654-017-0316-1","article-title":"The Swedish cause of death register","volume":"32","author":"Brooke","year":"2017","journal-title":"Eur J Epidemiol"},{"key":"2026012204413060100_bib15","first-page":"551","article-title":"Reference values for lung function tests in females. Regression equations with smoking variables","volume":"21","author":"Hedenstr\u00f6m","year":"1985","journal-title":"Bull Eur Physiopathol Respir"},{"key":"2026012204413060100_bib16","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3109\/03009738609178670","article-title":"Reference values for lung function tests in men: regression equations with smoking variables","volume":"91","author":"Hedenstr\u00f6m","year":"1986","journal-title":"Ups J Med Sci"},{"key":"2026012204413060100_bib17","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1056\/NEJMoa0909883","article-title":"Susceptibility to exacerbation in chronic obstructive pulmonary disease","volume":"363","author":"Hurst","year":"2010","journal-title":"N Engl J Med"},{"key":"2026012204413060100_bib18","doi-asserted-by":"crossref","first-page":"00235-2018","DOI":"10.1183\/23120541.00235-2018","article-title":"The superexacerbator phenotype in patients with COPD: a descriptive analysis","volume":"5","author":"Vanfleteren","year":"2019","journal-title":"ERJ Open Res"},{"key":"2026012204413060100_bib19","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1164\/rccm.201605-1014OC","article-title":"Acute exacerbations and lung function loss in smokers with and without chronic obstructive pulmonary disease","volume":"195","author":"Dransfield","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204413060100_bib20","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1136\/thoraxjnl-2011-201518","article-title":"Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality","volume":"67","author":"Suissa","year":"2012","journal-title":"Thorax"},{"key":"2026012204413060100_bib21","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2147\/COPD.S149633","article-title":"Economic burden of COPD in a Swedish cohort: the ARCTIC study","volume":"13","author":"Lisspers","year":"2018","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026012204413060100_bib22","doi-asserted-by":"crossref","first-page":"1900235","DOI":"10.1183\/13993003.00235-2019","article-title":"Extrafine triple therapy in patients with symptomatic COPD and history of one moderate exacerbation","volume":"53","author":"Singh","year":"2019","journal-title":"Eur Respir J"},{"key":"2026012204413060100_bib23","doi-asserted-by":"crossref","first-page":"1901921","DOI":"10.1183\/13993003.01921-2019","article-title":"The effect of exacerbation history on outcomes in the IMPACT trial","volume":"55","author":"Halpin","year":"2020","journal-title":"Eur Respir J"},{"key":"2026012204413060100_bib24","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1378\/chest.09-2029","article-title":"Increased risk of myocardial infarction and stroke following exacerbation of COPD","volume":"137","author":"Donaldson","year":"2010","journal-title":"Chest"},{"key":"2026012204413060100_bib25","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1164\/rccm.201711-2239OC","article-title":"Exacerbations of chronic obstructive pulmonary disease and cardiac events. A post hoc cohort analysis from the SUMMIT randomized clinical trial","volume":"198","author":"Kunisaki","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012204413060100_bib26","doi-asserted-by":"crossref","first-page":"106518","DOI":"10.1016\/j.rmed.2021.106518","article-title":"Large underreporting of COPD as cause of death-results from a population-based cohort study","volume":"186","author":"Lindberg","year":"2021","journal-title":"Respir Med"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/208\/2\/163\/66434170\/ajrccm_208_2_163.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/208\/2\/163\/66434170\/ajrccm_208_2_163.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T09:41:47Z","timestamp":1769074907000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/208\/2\/163\/8427855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":26,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,7,15]]},"published-print":{"date-parts":[[2023,7,15]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.202209-1774oc","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,7]]},"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"2022-09-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}